Sandbox vidit

Atrial flutter

Unstable

Stable

❑ Look for the presence of any of these: ❑ Chronic heart failure ❑ Hypotension ❑ Acute myocardial infarction

❑ Administer anticoagulation therapy based on the risk of stroke, if total duration of flutter > 48 hours ❑ Administer rate control therapy (AV nodal blockers) THEN ❑ Attempt conversion ❑ DC cardioversion ❑ Atrial pacing ❑ Pharmacological cardioversion

❑ Assess need for therapy to prevent recurrence

❑ Administer antiarrythmic therapy to prevent recurrences ❑ Consider catheter ablation if antiarrhythmic therapy fails

Anticoagulation Therapy

Shown below are tables depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with Atrial flutter.

Anticoagulation Therapy No risk factors ▸ Aspirin 81-325 mg daily 1 Moderate risk factor ▸ Aspirin 81-325 mg daily OR ▸ Warfarin (INR 2.0 to 3.0, target 2.5) Any high risk factor or more than 1 moderate risk factor ▸ Warfarin (INR 2.0 to 3.0, target 2.5)

Low Risk Factors	Moderate Risk Factors	High Risk Factors
▸ Female gender ▸ Age 65-74 years ▸ Coronary artery disease ▸ Thyrotoxicosis	▸ Age ≥ 75 years ▸ Hypertension ▸ Heart failure ▸ LV ejection fraction ≤ 35% ▸ Diabetes mellitus	▸ Previous stroke, TIA or embolism ▸ Mitral stenosis ▸ Prosthetic heart valve

Acute management of atrial flutter

Acute management of atrial flutter Proposed therapy Recommendation stable flutter ▸ Conversion ▸ Atrial or transesophageal pacing or ▸ DC cardioversion or ▸ Ibutilide or ▸ Flecainide or ▸ Propafenone or ▸ Sotalol or ▸ Procainamide or ▸ Amiodarone ▸ Rate control ▸ Beta blockers or ▸ Verapamil or diltiazem or ▸ Digitalis or ▸ Amiodarone

Acute management of atrial flutter Proposed therapy Recommendation Unstable atrial flutter ▸ Conversion ▸ DC cardioversion ▸ Rate control ▸ Beta blockers or ▸ Verapamil or diltiazem or ▸ Digitalis or ▸ Amiodarone Long term management of atrial flutter Long term management of atrial flutter Proposed therapy Recommendation ▸ First episode and well-tolerated atrial flutter ▸ Cardioversion alone or ▸ Catheter ablation ▸ Recurrent and well-tolerated atrial flutter ▸ Catheter ablation or ▸ Dofetilide or ▸ Amiodarone or Sotalol or Flecainide or Quinidine or Propafenone or Procainamide or Disopyramide ▸ Poorly tolerated atrial flutter ▸ Catheter ablation ▸ Atrial flutter appearing after use of class Ic agents or amiodarone for treatment of AF ▸ Catheter ablation or ▸ Stop current drug and use another ▸ Symptomatic non–CTI-dependent flutter after failed antiarrhythmic drug therapy Catheter ablation Pharmacological cardioversion Pharmacological Cardioversion for Atrial Flutter Drug Dosage ▸ Flecainide (class I, level of evidence A) ▸ Oral: 200 to 300 mg ▸ Intravenous: 1.5 to 3.0 mg/kg, over 10 to 20 min ▸ Ibutilide (class I, level of evidence A) ▸ Intravenous: 1 mg over 10 min, repeat 1 mg if necessary ▸ Propafenone (class I, level of evidence A) ▸ Oral: 600 mg ▸ Intravenous: 1.5 to 2.0 mg/kg, over 10 to 20 min ▸ Amiodarone (class IIa, level of evidence A) ▸ Oral: Inpatient ▸ 1.2 to 1.8 g per day in divided dose until a maximum of 10 g ▸ Followed by a maintenance dose of 200 to 400 mg per day or 30 mg/kg Outpatient ▸ 600 to 800 mg per day divided dose until a maximum of 10 g ▸ Followed by a maintenance dose of 200 to 400 mg per day ▸ Intravenous: 5 to 7 mg/kg, over 30 to 60 min Followed by 1.2 to 1.8 g per day continuous IV OR 5 to 7 mg/kg, in divided oral doses until a maximum of 10 g Followe by a maintenance dose of 200 to 400 mg per day Antiarrhythmic Therapy Maintenance of Sinus Rhythm ▸ Amiodarone (100 to 400 mg) OR ▸ Disopyramide (400 to 750 mg) OR ▸ Dofetilide (500 to 1000 mcg) OR ▸ Flecainide (200 to 300 mg) OR ▸ Procainamide (1000 to 4000 mcg) OR ▸ Propafenone (450 to 900 mg) OR ▸ Quinidine (600 to 1500 mg) OR ▸ Sotalol (160 to 320 mg)